- Home
- MNSB vs APLT Comparison
MNSB vs APLT Comparison
Compare MNSB & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNSB
- APLT
- Stock Information
- Founded
- MNSB 2003
- APLT 2016
- Country
- MNSB United States
- APLT United States
- Employees
- MNSB N/A
- APLT N/A
- Industry
- MNSB Major Banks
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- MNSB Finance
- APLT Health Care
- Exchange
- MNSB Nasdaq
- APLT Nasdaq
- Market Cap
- MNSB 170.1M
- APLT 178.6M
- IPO Year
- MNSB N/A
- APLT 2019
- Fundamental
- Price
- MNSB $19.70
- APLT $1.02
- Analyst Decision
- MNSB
- APLT Buy
- Analyst Count
- MNSB 0
- APLT 5
- Target Price
- MNSB N/A
- APLT $4.13
- AVG Volume (30 Days)
- MNSB 37.0K
- APLT 11.9M
- Earning Date
- MNSB 10-27-2025
- APLT 11-06-2025
- Dividend Yield
- MNSB 2.05%
- APLT N/A
- EPS Growth
- MNSB N/A
- APLT N/A
- EPS
- MNSB N/A
- APLT N/A
- Revenue
- MNSB $64,604,000.00
- APLT $121,000.00
- Revenue This Year
- MNSB $23.19
- APLT N/A
- Revenue Next Year
- MNSB $2.92
- APLT $5,931.24
- P/E Ratio
- MNSB N/A
- APLT N/A
- Revenue Growth
- MNSB N/A
- APLT N/A
- 52 Week Low
- MNSB $15.00
- APLT $0.30
- 52 Week High
- MNSB $22.98
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- MNSB 26.62
- APLT 63.41
- Support Level
- MNSB $20.07
- APLT $0.56
- Resistance Level
- MNSB $20.52
- APLT $1.32
- Average True Range (ATR)
- MNSB 0.38
- APLT 0.18
- MACD
- MNSB -0.16
- APLT 0.04
- Stochastic Oscillator
- MNSB 13.06
- APLT 64.91
About MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.